Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)

Global Liquid Biopsy Market: Analysis By Biomarkers (C-Tumor Cells, C-Tumor DNA, Vesicles), Cancer Type, By Product (Instruments, Reagents), By Region, By Country (2019 Edition): Opportunities and Forecast (2017-2024)

Executive Summary

According to Azoth Analytics research report, the Liquid Biopsy was valued at USD 899.55 million for the year 2018.

Over the recent years, Liquid Biopsy has been witnessing considerable growth on the back of growing focus on immunotherapy to cure cancer and shifting trend towards precision medicine along with high per capita healthcare expenditure and rapid adoption of novel diagnostic test by oncologist. Further, rising awareness for the early detection of cancer and sharp rise in its incidences have contributed to the growth rate of Liquid Biopsy Market.

Among the Circulating Biomarker, Ct- DNA is the most used biomarker for the diagnosis in pre and post cancerous stage, as it provides more comprehensive overview of the tumor genomic status. Ongoing research and clinical trials suggest that exosomes and nucleosomes, will provide more efficient diagnostic results and hence market will be growing in the forecast period.

In the forecast period, continuous research and development by private manufacturers, government organizations and designated government labs along with growing number of clinical trials in liquid biopsy is anticipated to provide momentum to the market growth. However, generation of revenue from the liquid biopsy is dependent upon the interest of third party payers, hindering the market growth.

Scope of the Report

Global Liquid Biopsy Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments
Regional Liquid Biopsy Markets - North America, Europe, APAC, ROW (Actual Period: 2017-2018, Forecast Period: 2019-2024)
  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments
Country Analysis – U.S., Germany, France, Japan (Actual Period: 2017-2018, Forecast Period: 2019-2024)
  • Liquid Biopsy Market: Size, Growth, Forecast
  • Analysis By Cancer Type: Lung, Breast, Colorectal, Prostate, Others
  • Analysis By Circulating Biomarker: CTC, ct-DNA, Vesicles
  • Analysis By Product Type: Reagents, Instruments
Company Analysis – Roche Diagnostics, Thermo Fisher Scientific, Guardant Health, Qiagen.

Other Report Highlights
  • Competitive Landscape - Sales, Segments, Market Share, Business Strategies
  • Investment and Partnerships
  • Product Analysis
  • Market Dynamics – Drivers and Restraints.
  • Market Trends
  • Porter Five Forces Analysis.
  • SWOT Analysis.


1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
3.1 Up coming of NGS technology
3.2 Asia Pacific region is expected to witness augmented growth in the forecast period.
4. Liquid Biopsy Market: Product Outlook
5. Global Liquid Biopsy Market: Growth and Forecast 5.1 By Value (2017-2024)
Table 1:Global Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
Table 2:Potential opportunities of liquid biopsy across cancer continuum care
Table 3:Key factors driving of change in the global oncology market
Table 4:Value based payment models for cancer care
Table 5:Biotechnology Research and Development Services Cost Index, In 2018
Table 6:Biopharmaceutical therapy selection market opportunity
Table 7:Top 10 Most Frequent Cancer in Females, World, (Age−standardised incidence rate per 100,000)
Table 8:Top 10 Most Frequent Cancer Deaths in Females, World, (Age−standardised incidence rate per 100,000 women)
Table 9:Global Prevalence of Different Type of Cancer, 2017 (In Thousands)
Table 10:Global Prevalence of Prostate Cancer (2013-2017, Thousands)
Table 11:Prevalence and Epidemiology of Cancer Worldwide
Table 12:5 Year Survival Rate, Breast and Colorectal Cancer
6. Global Liquid Biopsy Market: Segment Analysis
6.1 Global Liquid Biopsy Market Size, By Cancer Type: Breakdown (%)
Table 13: Global Liquid Biopsy Market Size, By Type, 2024 (In %)
6.2 Global Lung Cancer Liquid Biopsy Market, By Value (2017-2024)
Table 14: Global Lung Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
6.3 Global Breast Cancer Liquid Biopsy Market, By Value (2017-2024)
Table 15: Global Breast Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
6.4 Global Colorectal Cancer Liquid Biopsy Market, By Value (2017-2024)
Table 16: Global Colorectal Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
6.5 Global Prostate Cancer Liquid Biopsy Market, By Value (2017-2024)
Table 17: Global Prostate Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
6.6 Global Others Liquid Biopsy Market, By Value (2017-2024)
Table 18: Global Other Cancer Market, By Value, Forecast, 2019-2024 (USD Million)
6.7 Market attractiveness of Global Liquid Biopsy Market- By Cancer Type
Table 19: Market Opportunity Chart of Global Liquid Biopsy Market – By Cancer Type, By Value (Year - 2024)
6.8 Global Liquid Biopsy Market Size, By Circulating Biomarker: Breakdown (%)
Table 20: Global Liquid Biopsy Market Size, By Type, 2024 (In %)
6.9 Global CTC Liquid Biopsy Market, By Value (2017-2024)
Table 21: Global CTC Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
6.10 Global ct-DNA Liquid Biopsy Market, By Value (2017-2024)
Table 22: Global ct-DNA Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
6.11 Global Vesicle Liquid Biopsy Market, By Value (2017-2024)
Table 23: Global Vesicles Biomarker Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
6.12 Market attractiveness of Global Liquid Biopsy Market- By Circulating Biomarker
Table 24: Market Opportunity Chart of Global Liquid Biopsy Market - By Circulating Biomarker, By Value (Year - 2024)
6.13 Global Liquid Biopsy Market Size, By Product Type: Breakdown (%)
Table 25: Global Liquid Biopsy Market Size, By Type, 2024 (In %)
6.14 Global Reagent Liquid Biopsy Market, By Value (2017-2024)
Table 26: Global Reagent Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
6.15 Global Instrument Liquid Biopsy Market, By Value (2017-2024)
Table 27: Global Instrument Liquid Biopsy Market, By Value, Forecast, 2019-2024 (USD Million)
7. Global Liquid Biopsy Market: Regional Analysis
7.1 Global Liquid Biopsy Market Size, By Region : Breakdown (%)
Table 28 : Market Opportunity Chart of Global Liquid Biopsy Market - By Product Type, By Value (Year - 2024)
7.1.1 Global Liquid Biopsy Market Size, By Region, 2024 (%)
Table 29: Global Healthcare Landscape, By Select Region
Table 30: Global Liquid Biopsy Market Size, By Region, 2024 (%)
7.2 North America Liquid Biopsy Market: Growth and Forecast
7.2.1 By Value (2017-2024)
Table 31: North America Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
Table 32: North America GDP, 2012-2017 (USD Trillion)
Table 33: North America GDP per capita, current prices, 2013-2023F (In USD)
Table 34 Prevalence of Different Type of Cancer in North America in year 2016 & 2017 ( In Hundreds)
Table 35: North America, Cancer Incidence (In Millions)
Table 36: North America, Cancer Incidence, 2019 (In %)
Table 37: North America Population above 65 year, 2015, 2030F, & 2050F (In Millions)
Table 38: North America GDP, 2012-2017 (USD Trillion)
Table 39: North America GDP per capita, current prices, 2013-2023F (In USD)
7.2.2 By Cancer Type, By Value (2017-2024)
Table 40: North America Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.2.3 By Circulating Biomarker, By Value (2017-2024)
Table 41: North America Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.2.4 By Product Type, By Value (2017-2024)
Table 42: North America Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.3 North America Liquid Biopsy Market: Country Analysis (U.S)
7.3.1 U.S Liquid Biopsy Market, By Value (2017-2024)
Table 43: USA Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
Table 44: Leading Sites of New Cancer Cases in the United States amongst Males, 2018 (In %)
Table 45: Leading Sites of New Cancer Cases in the United States amongst Females, 2018 (In %)
Table 46: Estimated New Cases of Cancer in the United States, By Type 2018 (In %)
Table 47: Estimated New Cases of Cancer in the United States, 2014-2018 (In Thousands)
Table 48: Estimated New Cases of Cancer in the United States, By State, 2018
Table A: Estimated Numbers of US Cancer Survivors (As of January 1, 2016)
Table B: Estimated Numbers of US Cancer Survivors (As of January 1, 2026F)
Table 49: Percentage of adults aged 18-64 with insurance coverage in United States, By Poverty status, In 2018
Table 50: Percentage of individuals with insurance coverage in United States, By Age Group, In 2018
Table 51: Medical and Healthcare Research & Development Spending, 2014-2017 (In USD Million)
Table 52: Research and Development Expenditure of total U.S. Pharmaceutical Industry, 2013-2017, (USD Billion)
7.3.2 U.S Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
Table 53: US Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.3.3 U.S Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
Table 54: US Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.3.4 U.S Liquid Biopsy Market, By Product Type, By Value (2017-2024)
Table 55: US Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.4 Europe Liquid Biopsy Market: Growth and Forecast
7.4.1 By Value (2017-2024)
Table 56: Europe Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
Table 57 Europe, Cancer Incidence, 2019E-2035F (In Millions)
Table 58: Europe, Cancer Incidence, By Type, 2019E
Table 59 Prevalence of Different Type of Cancer in Western Europe in year 2016 & 2017 ( In Thousands)
Table 60: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Table 61: GDP, Europe Region, By Select Country, 2017 (In Trillion USD)
7.4.2 By Cancer Type, By Value (2017-2024)
Table 62: Europe Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.4.3 By Circulating Biomarker, By Value (2017-2024)
Table 63: Europe Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.4.4 By Product Type, By Value (2017-2024)
Table 64: Europe Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.5 Europe Liquid Biopsy Market: Country Analysis (Germany, France)
7.5.1 Germany Liquid Biopsy Market, By Value (2017-2024)
Table 65: Germany Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
Table C: Germany, Healthcare Related Statistics, 2017
Table 66: Germany, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
Table 67: Prevalence of Different Type of Cancer in Germany in year 2016 & 2017 ( In Hundreds)
Table 68 : German Pharmaceutical companies expenditure on R&D, In Million Euros
Table 69: Germany, Population ages 65 and above, 2012-2018 (% total)
7.5.2 Germany Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
Table 70: Germany Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.5.3 Germany Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
Table 71: Germany Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.5.4 Germany Liquid Biopsy Market, By Product Type, By Value (2017-2024)
Table 72: Germany Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.5.5 France Liquid Biopsy Market, By Value (2017-2024)
Table 73: France Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
Table 74: France, Number of Biotech Companies, By Type, 2017
Table 75: France, Prevalence of Cancer, 2018, (% of total)
Table 76: Healthcare expenditure in France ( as a % of GDP)
Table 77: Healthcare spending pattern in France, In 2016 & 2050, In USD $
7.5.6 France Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
Table 78: France Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.5.7 France Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
Table 79: France Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.5.8 France Liquid Biopsy Market, By Product Type, By Value (2017-2024)
Table 80: France Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.6 APAC Liquid Biopsy Market: Growth and Forecast
7.6.1 By Value (2017-2024)
Table 81: APAC Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
Table 82 : Estimated number of deaths from prostate cancer in 2012 and 2030
Table 83: World health expenditure as % of GDP
Table 84: Population ages 65 and above, APAC Region, By Select Countries, 2017 (% of total)
Table 85: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
Table 86: APAC, GDP, By Select Country, 2017 (In USD Trillion)
7.6.2 By Cancer Type, By Value (2017-2024)
Table 87: APAC Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.6.3 By Circulating Biomarker, By Value (2017-2024)
Table 88: APAC Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.6.4 By Product Type, By Value (2017-2024)
Table 89: APAC Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.7 APAC Liquid Biopsy Market: Country Analysis (Japan)
7.7.1 Japan Liquid Biopsy Market, By Value (2017-2024)
Table 90: Japan Liquid Biopsy Market, By Value, 2017-2024 (USD Million)
Table 91: Japan, Cancer Prevalence, By Type, (2018)
Table 92: Proportional mortality in Japan, In 2018
Table 93: Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 94: Japan, Population ages 65 and above, 2012-2018 (% of total)
7.7.2 Japan Liquid Biopsy Market, By Cancer Type, By Value (2017-2024)
Table 95: Japan Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.7.3 Japan Liquid Biopsy Market, By Circulating Biomarker, By Value (2017-2024)
Table 96: Japan Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.7.4 Japan Liquid Biopsy Market, By Product Type, By Value (2017-2024)
Table 97: Japan Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
7.8 ROW Liquid Biopsy Market: Growth and Forecast
7.8.1 By Value (2017-2024)
Table 98: ROW Liquid Biopsy Market Size, By Value, 2017-2024 (USD Million)
Table 99 : Middle East and North Africa, GDP, 2012-2017 (In USD Trillion)
Table 100 : Latin America and Caribbean, Share of Urban Population in Total Population, 2012-2017 (In %)
Table 101: Prevalence of Different Type of Cancer in Middle East and North Africa in year 2016 & 2017 ( In Hundreds)
Table 102: Prevalence of Different Type of Cancer in Brazil in year 2016 & 2017 ( In Hundreds)
Table 103: Population ages 65 and above, By Select Country, 2017 (% of total)
Table 104: Population ages 60 and above, By Select Country, 2050 (% of total)
7.8.2 By Cancer Type, By Value (2017-2024)
Table 105: ROW Liquid Biopsy Market: By Cancer Type, By Value, 2017-2024 (USD Million)
7.8.3 By Circulating Biomarker, By Value (2017-2024)
Table 106: ROW Liquid Biopsy Market: By Circulating Biomarker, By Value, 2017-2024 (USD Million)
7.8.4 By Product Type, By Value (2017-2024)
Table 107: ROW Liquid Biopsy Market: By Product Type, By Value, 2017-2024 (USD Million)
8. Global Liquid Biopsy Market: Competitive Landscape
8.1 Market share of Leading Global Companies
Table 108: Global Liquid Biopsy Market Share, By Select Company, 2018 (In %)
8.2 Global Liquid Biopsy Market : Investments and Partnerships
Table D: Recent Investments and Partnerships in Liquid Biopsy Market
8.3 Global Liquid Biopsy Market: Product Analysis
Table E: Liquid Biopsy assays using c- tumor cells, as yet
Table F : Liquid Biopsy assays using circulating free DNA, as yet
Table G: Ongoing clinical trials in ct- DNA liquid biopsy
Table H: Ongoing clinical trials in CTC liquid biopsy
9. Global Liquid Biopsy Market Dynamics
9.1 Global Liquid Biopsy Market Drivers
9.1.1 Rising incidence of cancer
9.1.2 Growing focus on immunotherapy to cure cancer
9.1.3 Growing government expenditure in cancer research
9.2 Global Liquid Biopsy Market Restraints
9.2.1 Technology is dependent upon the interest shown by third party payers
9.3 Global Liquid Biopsy Market Trend
9.3.1 Adoption of precision medicine for curing cancer
9.3.2 Early detection of cancer
10. Porter's Five Forces Analysis
11. SWOT Analysis
12. Policy and Regulatory Landscape
13.Company Profiles
13.1 Guardant Health
Table 109: Guardant Health, Sales Revenue, 2016-2018 (USD Million)
Table 110: Guardant Health, Sales Revenue, By Segment, In 2018 (USD Million)
13.2 Roche Diagnostics
Table 111: Roche Diagnostics, Sales Revenue, 2014-2018 (USD Million)
Table 112: Roche Diagnostics, Sales Revenue, By Diagnostic Segment, In 2018 (USD Million)
Table 113: Roche Diagnostics, Molecular Diagnostics Sales Revenue, By Geographical Segment, In 2018 (USD Million)
13.3 Thermo Fisher Scientific
Table 114: Thermo Fisher Scientific, Sales Revenue, 2014-2018 (USD Million)
Table 115: Thermo Fisher Scientific, Sales Revenue, By Business Segment, In 2018 (USD Million)
Table 116: Thermo Fisher Scientific, Sales Revenue, By Geographical Segment, In 2018 (USD Million)
13.4 Qiagen
Table 117: Qiagen, Sales Revenue, 2014-2018 (USD Million)
Table 118: Qiagen, Sales Revenue, By Business Segment, In 2018 (USD Million)
Table 119: Qiagen, Sales Revenue, By Geographical Segment, In 2018 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook